Search Results for "Heart Failure"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Heart Failure. Results 221 to 230 of 277 total matches.

Influenza Vaccines for 2025-2026

   
The Medical Letter on Drugs and Therapeutics • Sep 29, 2025  (Issue 1738)
disease (recent MI or hospitalization for heart failure), use of a high-dose inactivated vaccine ...
Annual vaccination against influenza A and B viruses is recommended in the US for everyone ≥6 months old without a contraindication. Influenza vaccines available in the US for the 2025-2026 season are listed in Table 2.
Med Lett Drugs Ther. 2025 Sep 29;67(1738):153-8   doi:10.58347/tml.2025.1738a |  Show IntroductionHide Introduction

Drugs That Cause Sexual Dysfunction: An Update

   
The Medical Letter on Drugs and Therapeutics • Aug 07, 1992  (Issue 876)
, such as guanadrel (Hylorel), can cause impotence and ejaculatory failure. Centrally acting sympatholytics ...
Many commonly used drugs can interfere with sexual function in both men and women, causing loss of libido, interfering with erection or ejaculation in men, and delaying or preventing orgasm in women. Drug-related effects on sexual function may be difficult to distinguish from the effects of depression or disease, but most are reversible when drug use is stopped and sometimes when dosage is decreased. Since many patients are reluctant to talk about sexual difficulties, physicians may wish to ask about the possibility of drug-induced sexual dysfunction, particularly when they have...
Med Lett Drugs Ther. 1992 Aug 7;34(876):73-8 |  Show IntroductionHide Introduction

Pravastatin And Simvastatin for Hypercholesterolemia

   
The Medical Letter on Drugs and Therapeutics • Mar 08, 1991  (Issue 839)
mg/d and 16% with 40 mg/d (JF Walker and JA Tobert, Eur Heart J, 8 suppl E:93, 1987). Similar ...
Pravastatin (Pravachol - Bristol-Myers Squibb) and simvastatin (Zocor - Merck), two new inhibitors of cholesterol synthesis similar to lovastatin (Mevacor - Merck), have been marketed in Canada and several European countries and may soon be available in the USA for treatment of high plasma cholesterol concentrations. Drugs already marketed here for this indication were recently reviewed in The Medical Letter (Volume 33, page 1, January 11, 1991).
Med Lett Drugs Ther. 1991 Mar 8;33(839):18-20 |  Show IntroductionHide Introduction

Antibacterial Prophylaxis for Dental, GI and GU Procedures

   
The Medical Letter on Drugs and Therapeutics • Jul 18, 2005  (Issue 1213)
are based on those recommended by the American Heart Association for prevention of endocarditis. 2 ...
Many physicians believe that antimicrobial prophylaxis before procedures that may cause transient bacteremia can prevent endocarditis and prosthetic joint infection in patients at increased risk for these disorders. The effectiveness of this common practice has never been established by controlled trials in humans.
Med Lett Drugs Ther. 2005 Jul 18;47(1213):59-60 |  Show IntroductionHide Introduction

Clarithromycin in Patients with Coronary Artery Disease

   
The Medical Letter on Drugs and Therapeutics • May 21, 2018  (Issue 1547)
result in treatment failure in patients with pneumococcal infection. 13. Other possible pathogens ...
The FDA has warned that use of the macrolide antibiotic clarithromycin (Biaxin, and generics) may increase the risk of cardiovascular morbidity and mortality in patients with heart disease.
Med Lett Drugs Ther. 2018 May 21;60(1547):89-90 |  Show IntroductionHide Introduction

Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Chronic Weight Management (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024  (Issue 1708)
reactions ▶ Increased heart rate ▶ Renal impairment and acute renal failure ▶ Possible pancreatitis ...
View the Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Chronic Weight Management
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e1-2   doi:10.58347/tml.2024.1708d |  Show IntroductionHide Introduction

Drugs for Migraine

   
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023  (Issue 1678)
, and orthostatic hypotension. They should not be used in patients with decompensated heart failure. ANTISEIZURE ...
An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine pain without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine in most patients without vascular disease. Treatment of pain when it is still mild to moderate in intensity improves headache response and reduces the risk of recurrence.
Med Lett Drugs Ther. 2023 Jun 12;65(1678):89-96   doi:10.58347/tml.2023.1678a |  Show IntroductionHide Introduction

Testosterone Nasal Gel (Natesto) for Hypogonadism

   
The Medical Letter on Drugs and Therapeutics • May 11, 2015  (Issue 1468)
HYPOGONADISM — Failure of the testes to produce adequate amounts of testosterone can lead to loss of energy ...
The FDA has approved an intranasal gel formulation of testosterone (Natesto – Trimel/Endo) for replacement therapy in men with hypogonadism. Packaged in a metered-dose pump, Natesto is the first intranasal testosterone to become available in the US. Like other testosterone products, it is classified as a schedule III controlled substance. The FDA recently cautioned against using testosterone to treat low testosterone levels solely due to aging because the benefits and safety of such use have not been established, and there is a possible increased risk of myocardial infarction...
Med Lett Drugs Ther. 2015 May 11;57(1468):73-4 |  Show IntroductionHide Introduction

Safety of Aggressive Statin Therapy

   
The Medical Letter on Drugs and Therapeutics • Nov 22, 2004  (Issue 1196)
to ...
New guidelines from The National Cholesterol Education Program recommend, as a therapeutic option, lowering treatment goals for LDL cholesterol (LDL-C) from <100 mg/dL to <70 mg/dL for patients at very high risk for coronary heart disease and from 130 mg/dL to <100 mg/dL for those at moderately high risk. A likely consequence of these recommendations is increased use of statins and use of higher doses with a concomitant increase in adverse effects.
Med Lett Drugs Ther. 2004 Nov 22;46(1196):93-5 |  Show IntroductionHide Introduction

Lonapegsomatropin (Skytrofa) for Growth Hormone Deficiency

   
The Medical Letter on Drugs and Therapeutics • Feb 07, 2022  (Issue 1643)
following open heart or abdominal surgery, multiple accidental trauma, or acute respiratory failure ...
Lonapegsomatropin-tcgd (Skytrofa – Ascendis), a long-acting prodrug of recombinant human growth hormone (rhGH), has been approved by the FDA for once-weekly subcutaneous (SC) treatment of growth failure due to inadequate secretion of endogenous growth hormone in children ≥1 year old who weigh ≥11.5 kg. It is the first once-weekly rhGH product to be approved in the US; other available rhGH formulations are administered more frequently.
Med Lett Drugs Ther. 2022 Feb 7;64(1643):20-2 |  Show IntroductionHide Introduction